The Aurora family of serine/threonine kinases plays an important role in chromosome alignment, segregation and cytokinesis during mitosis. Recent studies have found aberrant expression of Aurora kinases in a variety of human solid tumors and hematological malignancies, suggesting they have a role in carcinogenesis. This review highlights the function of Aurora kinases in the regulation of mitosis and presents the rationale for these kinases as an anti-cancer target. We also review recently developed inhibitors of Aurora kinases.
expression of Aurora A in near diploid human breast epithelial cells induced similar centrosome abnormality, as well as induction of aneuploidy [7] . Other groups also found that conditional expression of Aurora A in murine mammary epithelium induced accumulation of binucleated cells and transformation when p53 was deleted [55] . These findings suggest that Aurora A can act as an oncogene.
Interestingly, Aurora A interacts with and inactivates the tumor suppressor p53; Aurora A phosphorylates p53 on Ser315, facilitating MDM-2-mediated degradation of p53 in cancer cell lines [56] . Aurora A phosphorylates p53 on Ser215 and abrogates its DNA-binding ability, resulting in inhibited transcriptional activity [57] .
Aurora A also interacts with the breast cancer susceptibility gene BRCA 1. Aurora A colocalizes with BRCA 1 in centrosomes and phophorylates BRCA 1 on Ser308, leading to impairment of its function as a G2/M checkpoint keeper [58] . Thus, it may also be involved in the carcinogenesis of breast cancer.
Overexpression of Aurora A causes resistance to Taxol-mediated apoptosis in cancer cells. Taxol, a tubulin depolymerizing agent, activates the spindle checkpoint in HeLa cells, but this is overridden by Aurora A, resulting in escape from apoptosis [59] .
Aurora B. The contribution of Aurora B to carcinogenesis has been less studied than that of Aurora A. Aurora B is located on chromosome 17p13.1, a region not typically amplified in human malignancies; however, overexpression of Aurora kinase B has been shown in a variety of human cancers, including glioblastoma multiforme [60] , malignant mesothelioma [61] , and hematological malignancies [15] . High levels of Aurora B are associated with adverse clinical outcomes in patients with endometrial carcinoma [62] . Forced expression of Aurora B in Chinese hamster embryo cells resulted in chromosome instability and increased tumor invasiveness in association with constitutive expression of phosphorylated (p)-histone H3 on Ser10 [63] , suggesting that Aurora B can act as an oncogene.
Aurora C. The involvement of Aurora C in carcinogenesis has been the least explored of all the Aurora kinase family. The few available studies found that Aurora C was overexpressed in colorectal, breast, and prostate cancers [5, 18] . The level of expression of Aurora C correlated with the degree of dysplastic change in colorectal cancer cells [18] . Forced expression of Aurora C in HeLA cells produced polyploidy, which was augmented by inactivation of p53 [64] . These observations suggest that Aurora C might be a promising molecular target for cancer treatment. Hesperadin. Hesperdin (Boehringer Ingelheim) is a novel indolinone with specific activity against Aurora B kinase, as it was shown to inhibit p-histone H3 with an IC 50 [51] . In addition, a recent study found that ZM447439 was active against hematological malignancies including AML and Philadelphia chromosome-positive ALL [15] . This study also found that cells expressing wild-type p53 were more sensitive to ZM447439-mediated growth inhibition than cells possessing the mutated p53 gene. These observations suggest that the p53-dependent post-mitotic checkpoint played an important role in Aurora kinase inhibitor-mediated apoptosis.
ZM447439 has not been developed in clinical trials.
MK0457
. MK0457 (VX-680; Merk/Vertex) is an ATP-competitive pan-Aurora kinase inhibitor (IC 50 0.6, 18, and 4.6 nM for Aurora A, B, and C, respectively) [ Table 1, 19] . In vitro study showed that MK0457 induced endoreduplication in cancer cells, a characteristic feature of phenotype mediated by inhibition of Aurora B kinase by RNA interference. Preclinical study showed that MK0457 inhibited proliferation of human myelogenous leukemia HL60 and colon cancer HCT116 cells in a murine xenograft model [19] . MK0457 effectively inhibited colony formation of freshly isolated AML cells with internal tandem duplication mutations in the fms-like tyrosine kinase (FLT3) gene [19] . MK0457 possesses many off-targets including FLT3 kinase. Interestingly, MK0457 was able to inhibit imatinib-or dasatinib-resistant ABL kinase mediated by T315I mutation [66] . A recent clinical study showed that MK0457 was active in individuals with imatinib-resistant CML or ALL patients possessing T315I-BCR/ABL mutation [66] . A phase 1 clinical trial of MK0457 in 22 heavily pre-treated patients found a recommended dose of 10 mg/m/h, continuous 24 h infusion for 5 days every 28 days. Neutropenia was the dose-limiting toxicity. One patient with pancreatic cancer and another with non-small-cell lung cancer achieved stable disease as their best response, which lasted over 6 months [67] .
AZD1152. AZD1152 (AstraZeneca) is a novel acetanilide-substituted
pyrazole-aminoquinazoline prodrug that is converted rapidly to the active drug AZD1152 hydroxy-QPA (AZD1152-HQPA) in human plasma [20] . AZD1152-HQPA is a specific and selective inhibitor of the enzymatic activity of Aurora B kinase (IC 50 0.37 nM versus 1368 nM for Aurora B and A kinases, respectively); the inhibitor had even lower activity against a panel of more than 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and ABL [ Table 1, 20, 22] . Preclinical studies showed that AZD1152 was active against a variety of solid tumors including colon, breast, and lung cancers, as well as myelogenous leukemia in a tumor xenograft model [21, 22] .
These studies demonstrated phosphorylated-histone H3 as a biomarker of Aurora inhibition. Of note, AZD1152 potentiated the anti-tumor effects of the tubulin depolymerizing agent vincristine and the topoisomerase II inhibitor daunorubicin in AML cells in vitro and in vivo [22] . In addition, AZD1152 was able to inhibit the proliferation of imatinib-resistant ALL cells with Philadelphia chromosome, although it was not active against BCR/ABL [22] .
A recent Phase 1 trial of AZD1152 in 19 patients showed that the maximum tolerated dose was 200 mg, given as a 2-h weekly infusion. As with MK0457, neutropenia was the dose-limiting toxicity. Stable disease for longer than 25 weeks was the best response achieved in three patients (one with melanoma, one with nasopharyngeal carcinoma and one with adenoid cystic carcinoma) [68] .
MLN8054.
MLN8054 is an orally available, potent and selective inhibitor of Aurora A kinase (IC 50 4 nM versus 172 nM for Aurora A and B kinase, respectively)
[ Table 1 PHA-739358 showed significant cross-reactivity with ABL in a biochemical assay, with an IC 50 of 25 nM [24] . Notably, PHA-739358 was active against T315I BCR/ABL mutation [69] . PHA-739358 is currently being evaluated in clinical trials in solid and hematological malignancies, including imatinib-resistant CML.
Thus, the inhibitors of Aurora kinase activity are well tolerated and produce some clinical benefits. Preclinical studies have found that inhibition of Aurora kinase A and B sensitizes malignant cells to apoptosis mediated by tubulin depolymerizing agents [22, 59] . Clinical trials are warranted to evaluate the efficacy of combining Aurora kinase inhibitor and this class of chemotherapeutic agents. 
